Atopic Dermatitis

Tapinarof cream demonstrated highly statistically significant improvement in the primary end point of vIGA-AD treatment success over vehicle at week 8.

Interim data from the clinical trial was presented in a poster at the South Beach Symposium, with itch reduction demonstrating immediacy and long-term capability.

A discussion among roundtable participants revolved around the importance of effective communication, the impact of prolonged use of topical steroids, and the need for trust building in recommending novel treatment options.

Exposure led to an increase in total plasma IgE levels but reduced epidermal thickening, mast cell number, and plasma histamine levels in the early stages of AD.

Atopic dermatitis flares are about more than just skin symptoms and are difficult to quantify, according to a study that asked patients to describe them.

Researchers explored the efficacy of a multistep treatment strategy in a younger patient population.

Investigators highlighted the importance of considering household second hand smoke exposure when evaluating adolescents with AD.

In a review of relevant research, investigators found that in many aspects, telemedicine services were as effective as in-office care visits for AD.

Functional magnetic resonance imaging response was utilized to test motor, somatosensory association cortex, perception, and sensory integration processing in a recent study.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the tolerability and low discontinuation rates of tapinarof for patients in AD clinical trials, as well as discuss the adverse events associated with the drug.

In a recent Dermatology Times Case-Based Roundtable Meeting, Tina Bhutani, MD, MAS, shared intriguing cases and insights about atopic dermatitis treatment challenges faced by patients with different lifestyles and hobbies.

A study explored the prioritization habits of both patients with atopic dermatitis and their caregivers when it comes to treatment.

In a recent study, prenatal opioid exposure was also linked to increased odds of infections and asthma, but not with allergies, anaphylaxis, orautoimmune conditions.

Adelaide A. Hebert, MD, FAAD, shares insight on the eczema area and severity index 75 (EASI75) results from the ADORING 1 and ADORING 2 clinical trials for use of tapinarof in AD.

Expert dermatologists review the validated investigator global assessment for AD (vIGA-AD) response in the ADORING 1 and ADORING 2 trials for tapinarof.

An expert in dermatology reviews the case of a 33-year-old male patient suffering from atopic dermatitis for the past 3 years. He breaks down the panel's conversation on the use of non-steroidal topicals and emphasizes how patient assistance programs can ease burden for patients and providers.

Shawn Kwatra, MD, presents a case involving a 73-year-old African American female seeking treatment for her atopic dermatitis. In this segment Dr Kwatra explains the panels thoughts and rationale behind the prescribed treatments, discussing how each option works and its limitations.

The FDA has added efficacy and safety data for patients ages 12 years and older with uncontrolled moderate-to-severe atopic dermatitis with hand and/or foot involvement.

The pooled analyses from Arcutis’ INTEGUMENT-1 and INTEGUMENT-2 studies were presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

Ten posters at the Winter Clinical Hawaii and Maui Derm Conferences will showcase investigational data to expand treatment options for patients with atopic dermatitis and chronic hand eczema.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the rapid itch reduction results found in the clinical trials for tapinarof in AD, as well as primary end points of the studies.

Expert dermatologists highlight the patient characteristics in the ADORING 1 and ADORING 2 trials, both focusing on tapinarof for the treatment of AD.

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Study findings suggest that Lavandula species, with their historical use in folk medicine, could emerge as valuable additions to AD treatment regimens. However, it's crucial to note that the efficacy of these oils is concentration-dependent.

Test your knowledge and explore a recent study on the relationship between alcohol consumption and skin diseases, including atopic dermatitis.

The topical therapy was more effective in patients with psoriasis and AD when compared to a vehicle control cream.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review clinical trial data for tapinarof cream, 1% in the treatment of AD.

Expert dermatologists discuss the use of nonsteroidal treatment formulations for the treatment of AD, focusing on a topical treatment, tapinarof cream, 1%.